



Question: What vaccines are available?

Answer: In the U.S., there are three vaccines being administered. The Pfizer/BioNTech and Moderna vaccines are *messenger RNA* (mRNA) vaccines. These were the first vaccines to become available in the U.S., mostly because so much research had been done to develop this method prior to the pandemic. So, although these are the first ever mRNA vaccines used in the U.S., this technique has been worked on by scientists since the 1990s. The pandemic brought increased attention and funding that allowed scientists to improve upon this existing technology and make it available. There is currently another mRNA vaccine being used in African countries against the Ebola virus. COVID-19 mRNA vaccines are two-doses that deliver one or more coronavirus genes into human cells, essentially giving the body temporary instructions to make harmless spike proteins to stimulate immunity. The result is that the body can produce its own antibodies against COVID-19.

The Pfizer/BioNTech vaccine was approved by the FDA in August 2021 for all people 16 years and older. Per the CDC, this vaccine is recommended to all people 12 years and older including those who are pregnant, lactating, trying to become pregnant, or planning to become pregnant soon. This approval is the first of its kind for an mRNA vaccine. The Pfizer vaccine is also available to 12 to 15-year-olds under an Emergency Use Authorization (EUA). In October 2021, the FDA's independent advisory committee recommended approval of another EUA so that the Pfizer vaccine can be made available to 5 to 11-year-olds. This is the first step in the approval process and more information will be available in the coming weeks. The Moderna mRNA vaccine is currently approved under an EUA for adults 18 and older.

The Johnson and Johnson vaccine is made using the viral vector method. This technology has been used in vaccine development since the 1970s, and relies on a harmless virus (the vector) to deliver the vaccine. In the one-dose viral vector COVID-19 vaccines, a gene for the viral spike protein is inserted into another inactive virus to deliver the gene to human cells. This causes the immune system to recognize the virus and quickly respond by producing antibodies.

Use of the Johnson and Johnson vaccine was briefly suspended when data showed an increased risk of a rare adverse event involving low platelet count and blood clots in vaccine recipients under 50 years old who identified as women. This event occurred in seven per 1 million vaccinated people in this demographic in the U.S. In people over 50 years old, and people who identified as men of any age, this event was even more rare. On April 23, 2021, the FDA and CDC recommended that use of the vaccine continue due to benefits outweighing the risks. According

to the CDC, pregnant people and those under 50 are eligible to receive this vaccine but should be educated on the alternative (mRNA) vaccines that are also available.¹

Question: How effective are the different vaccines at preventing COVID-19?

Answer: This is a very difficult question to answer due to newly evolving COVID-19 variants and disease distribution. The more contagious a variant is, and the more people who are spreading it, can change the answers to this question. Initial vaccine efficacy was shown to be around 95% for the mRNA vaccines (Pfizer BioNTech and Moderna) and 72% for the viral vector vaccine (Johnson and Johnson), but these numbers only capture how the vaccines performed under the controlled conditions of a clinical trial. The initial *efficacy* differs from the vaccines' real-world *effectiveness* and does not account for factors such as newer variants, vaccine response in different people, and how protection may lessen or change over time. Even as these numbers evolve, it's important to note that all the available vaccines remain extremely effective at preventing severe disease, hospitalization, and death. These definitions may help you as you read other articles and interpret data:

Vaccine efficacy is defined as the percent decrease in disease incidence in a vaccinated group versus an unvaccinated group in optimal conditions (such as in a randomized control trial).

Vaccine effectiveness measures a vaccine's ability to prevent any undesired outcome such as infection, severe disease, hospitalization, or death in real world conditions.

For more information on this topic, including the latest information on vaccine efficacy and effectiveness, visit:

[Yale Medicine Vaccine Article](https://bit.ly/3pxvBNO) (<https://bit.ly/3pxvBNO>)

[Vaccine Efficacy and Effectiveness-CDC](https://bit.ly/2ZoQpeF) (<https://bit.ly/2ZoQpeF>)

Question: What is the available evidence on COVID-19 vaccination in pregnancy and while lactating?

Answer: When the vaccines were first rolled out in late 2020 and early 2021, no official U.S. recommendations were given for or against vaccination during pregnancy/lactation. This is primarily because pregnant and lactating people were not included in the first COVID-19 vaccine trials. Some of the first pregnant and lactating vaccine recipients were healthcare workers. Then in April 2021, pregnant people in the U.S. general population were offered the vaccine.

The CDC tracks pregnant people who receive a COVID-19 vaccine and, as of October 18, 2021, there were 168,157 self-reported pregnant people who completed the





CDC's "v-safe after vaccination health checker." Of this group, 5,104 vaccinated pregnant people enrolled in the "v-safe pregnancy registry" to be followed throughout their pregnancies and beyond. In this group, there was no significant increase in the rate of pre-term birth, miscarriage, placental abnormalities, or congenital anomalies compared to the general population. So far, most v-safe pregnancy registry participants received their vaccines in the third trimester of pregnancy.²

A study published in the American Journal of Obstetrics and Gynecology (AJOG) in March 2021 compared vaccine response in 131 reproductive-age vaccine recipients (84 pregnant, 31 lactating, and 16 non-pregnant). All participants in this study received an mRNA vaccine, with about half receiving Pfizer/BioNTech and half receiving Moderna. Immune responses were similar in the three groups (pregnant, lactating, and non-pregnant). In the pregnant study group, the immune responses of participants did not differ based on when they received the vaccine in pregnancy, and the vaccine generated higher antibody levels than seen in natural COVID-19 infection. Immune protection from vaccine-generated antibodies passed to babies through the placenta and human milk, and these antibodies were detected in cord blood and human milk samples.³

Researchers are continuing to publish many smaller studies about vaccination in lactating people. Early data show that antibodies to the COVID-19 virus successfully transfer from vaccinated parents to babies who are ingesting human milk. Small studies have also demonstrated that, while antibodies do successfully transfer, the components of the mRNA COVID-19 vaccines do not transfer via human milk.⁴ While this research is encouraging, and in line with other vaccines given during pregnancy, more information is needed to determine if the antibodies transferred in human milk and cord blood sufficiently protect babies from COVID-19.

Question: Are the vaccines approved for use during pregnancy?

Answer: In response to the growing body of evidence demonstrating the safety of COVID-19 vaccines for pregnant and lactating people, many major organizations began recommending vaccination for this population in August 2021. This list currently includes the Federal Drug Administration (FDA), Centers for Disease Control and Prevention (CDC), American College of Obstetricians and Gynecologists (ACOG), American College of Nurse Midwives (ACNM), the Society for Maternal Fetal Medicine (SMFM), and the National Institute for Health and Care Excellence in the United Kingdom (NICE), among others. Also in August 2021, the FDA granted full approval to

the Pfizer/BioNTech vaccine for all individuals 16 years and older. The approval does not specifically state that pregnant people are included, but it does not exclude them. At the time this handout was written, the Moderna and Johnson and Johnson vaccines remain approved under Emergency Use Authorization (EUA).

Question: Does COVID-19 cause more serious disease in pregnancy? What are the known risks of vaccinating during pregnancy compared to the known risks of COVID-19 during pregnancy?

Answer: Pregnant people with COVID-19 infection are at higher risk for more severe disease—especially for those who are unvaccinated. A recent study by the National Institute of Health Research (NIHR) showed that 99.5% of pregnant people admitted to the hospital with COVID-19 were unvaccinated. When compared with non-pregnant people, pregnant people with COVID-19 were at an increased risk of intensive care admission, respiratory support, and pneumonia.⁵

Two other known risks of COVID-19 in pregnancy are pre-term birth and preeclampsia. In 2021, researchers analyzed California Vital Statistics birth certificate records of more than 200,000 births and found a 60% increased risk in very pre-term birth (giving birth at <32 weeks of pregnancy) in participants with a COVID-19 diagnosis. Additionally, there was a 40% increased risk in pre-term birth (giving birth at <36 weeks of pregnancy), and a 10% increased risk in early term birth (giving birth between 37 weeks 0 days and 38 weeks 6 days of pregnancy) in participants with a COVID-19 diagnosis. These increased risks are relative to the control or non-COVID-19 group.⁶

Also in 2021, researchers reviewed 28 different studies made up of 790,954 pregnant people, 15,524 of which were diagnosed with COVID-19. The risk of developing preeclampsia was 1.58 times higher in the COVID-19 group as compared to the pregnant people without COVID-19. Both symptomatic and asymptomatic COVID-19 infections resulted in significantly higher rates of preeclampsia, though the rate was slightly higher in symptomatic cases.⁷

A study published in the New England Journal of Medicine in April 2021 provides the most comprehensive data thus far about people who received an mRNA COVID-19 vaccine during pregnancy. This data was gathered from three CDC sources—the 'v-safe after vaccination health checker', the v-safe pregnancy registry, and VAERS (the Vaccine Adverse Event Reporting System). The data showed that compared with non-pregnant people who were vaccinated, pregnant people who received an mRNA vaccine were more likely to report injection site pain and less likely to report





other systemic reactions including headache, fever, chills, and muscle pain. Pregnant people were also more likely to report nausea and vomiting after their second dose of vaccine, but they were not more likely to report any other serious vaccine reactions as compared to non-pregnant people. There were no significant differences in the rates of adverse pregnancy outcomes including pregnancy loss, pre-term birth, and small for gestational age newborns between vaccinated pregnant people in the study group and pre-pandemic rates of these events.⁸

Another study, currently published as a letter to the editor on October 20, 2021, in the *New England Journal of Medicine*, looked at the early (first trimester) miscarriage rate in pregnant people who received a COVID-19 vaccine during pregnancy and pregnant people who did not. The study took place in Norway and researchers reviewed the records of about 18,000 pregnant people—about 14,000 of whom had ongoing pregnancies and about 4,000 of whom had early miscarriages—from Norwegian registry data. The study found no evidence of increased early pregnancy loss in the participants who received a COVID-19 vaccine, adding to the increasing evidence of the safety of COVID-19 vaccines in pregnancy.¹

Question: Has research demonstrated a link between COVID-19 and infertility?

Answer: There is no evidence that demonstrates a link between COVID-19 vaccination and infertility for egg-carriers. Theories about a possible connection come from what some believe is a structural similarity of the SARS-CoV-2 spike protein and syncytin-1, a protein that helps form the placenta and is necessary for the development of an embryo in utero. This misleading theory, circulated by a known anti-vaccination group, proposed that an immune response against the spike protein could also cause an immune response against syncytin-1, thus potentially impacting pregnancy. However, experts in immunology, infectious disease, and pregnancy have refuted this idea.

A study published in September 2021 studied this idea in people already undergoing in vitro fertilization for fertility treatment. Study participants were divided into three groups: 1) those who had COVID-19 antibodies from prior natural infection, 2) those who had COVID-19 antibodies from prior vaccination, and 3) those who did not have antibodies from infection or vaccination. All vaccinated participants received one of the two available mRNA vaccine regimens. In the study, 143 unique frozen embryo transfers (FETs) were analyzed. Standard screening and protocols for FET were followed. The researchers found no difference in pregnancy success rates between the three groups.⁹

Another study explored this theory by directly comparing the placentas of birthing people who had received the COVID-19 mRNA vaccine in pregnancy versus those who had not received the vaccine. In this study, researchers at Northwestern University examined the placentas of 84 vaccinated people and 116 unvaccinated people shortly after giving birth. All study participants had negative COVID-19 polymerase chain reaction (PCR) tests. The vaccinated group did not have a higher rate of placental abnormalities as compared to the unvaccinated group. The study, published in *Obstetrics and Gynecology* in August 2021, further refutes theories of any association between COVID-19 vaccines and placental health, and adds to the growing body of evidence that COVID-19 mRNA vaccines are safe in pregnancy and the preconception period.¹⁰

Another much discussed topic regarding fertility is the possible association between COVID-19 vaccination and changes in menstrual cycles. The United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHPR) has received over 30,000 reports of such events to their yellow card surveillance system—a self-reporting system similar to VAERS in the United States. Reproductive health experts suggest that these changes are likely hormonal and the result of the body's immune response from vaccination, rather than a reaction to specific components of the vaccine. These reports have come from both mRNA and viral vector vaccine recipients, and most people who reported these changes had their abnormal menstrual cycles return to normal after one cycle. More research is needed to investigate this possible link. For anyone tracking their menstrual cycles in hopes of preventing or achieving pregnancy, this is a potentially important consideration.¹¹

Question: What can we expect in terms of future research about vaccination in pregnancy?

Answer: A study called “Preg-CoV” is the first randomized trial to directly study COVID-19 vaccination in pregnancy. The study is currently taking place in the United Kingdom at the National Institute of Health Research (NIHR) Southampton Clinical Research Facility and is enrolling pregnant people between the ages of 18-44 and in weeks 13-34 of pregnancy. The primary goal of the study is to determine the best timing between doses for the mRNA COVID-19 vaccines in pregnancy. Study scientists will analyze blood and human milk samples from pregnant study participants, as well as blood samples from babies born to study participants. Scientists hope the results will help us understand how vaccines can protect pregnant people and how that protection can potentially transfer to newborns. Initial results are expected at the end of 2021.¹²





Question: Is there a new recommendation regarding booster shots for pregnant people?

Answer: At the time this handout was written, there is not currently a specific recommendation or backing data to suggest that all pregnant people should receive a COVID-19 booster shot. The U.S. recommendation is currently that immunocompromised individuals, those over 65, and adults who live or work in a high-risk setting are eligible to receive a third dose, or “booster shot”. Those who initially received an mRNA vaccine (Pfizer-BioNTech or Moderna) are candidates for a booster beginning six months after their second dose. Those who received a viral vector (Johnson and Johnson) vaccine are candidates for a booster beginning two months after their initial single dose. The FDA has also authorized the mixing of approved and available vaccine brands. This means that booster doses of any brand may be administered to the approved population regardless of what brand was used for their primary vaccine.¹³

Disclaimer & Copyright:

This information does not substitute for a care provider-patient relationship and should not be relied on as personal medical advice. Any information should not be acted upon without professional input from one's own healthcare provider. © 2021. All rights reserved. Evidence Based Birth[®] is a registered trademark. Permission is granted to reproduce this handout in print as long as only the most recently updated version is used and complete credit given to the authors. Handouts may be distributed freely in print but not sold. This PDF may not be posted online.

A NOTE FROM EBB

The research on vaccines (including the research on booster doses) is rapidly changing, and new studies may be published that update some of the current evidence written about in this handout. Below is a list of resources that may be helpful to pregnant people and those trying to conceive in navigating vaccination decisions:

- [COVID-19 and Pregnancy CDC Page \(https://bit.ly/3mexGn\)](https://bit.ly/3mexGn)
- [NIH-How COVID-19 Affects Pregnancy \(https://bit.ly/3pL10QO\)](https://bit.ly/3pL10QO)
- [Preg-CoV Trial Information \(https://bit.ly/3bd2dmE\)](https://bit.ly/3bd2dmE)

1. CDC Press Release. CDC Recommends Use of Johnson and Johnson's Janssen COVID-19 Vaccine Resume. Updated online August 27, 2021.
2. CDC Website. COVID-19 Vaccines While Pregnant or Breastfeeding. Published online October 7, 2021.
3. Gray K., Bordt E., Atyeo C., et al. (2021). COVID-19 vaccine response in pregnant and lactating women: a cohort study. *AJOG*. 2021 Mar 25.
4. Golan Yarden, Prael Mary, Cassidy Arianna, et al. (2021). Evaluation of Messenger RNA From COVID-19 BTN162b2 and mRNA-1273 Vaccines in Human Milk. *JAMA Pediatrics*. 2021 Oct.
5. Vousden Nicola, Ramakrishnan Rema, Bunch Kathryn, et al. (2021). Impact of SARS-COV-2 variant on the severity of maternal infection and perinatal outcomes: Data from the UK Obstetric Surveillance System national cohort. *medRxiv*. [preprint]
6. Karasek Deborah, Baer Rebecca, McLemore Monica R, et al. (2021). The Association of COVID-19 Infection in Pregnancy with Preterm Birth: A Retrospective Cohort Study in California. *The Lancet Regional Health-Americas*. 2021 July 30.
7. Conde-Agudelo Agustin, Romero Roberto (2021). SARS-CoV-2 infection during pregnancy and risk of preeclampsia: a systematic review and meta-analysis. *American Journal of Obstetrics and Gynecology*. 2021 July 21.
8. Shimabukuro Tom, Kim Shin, Myers Tanya, et al. (2021). Preliminary Findings of mRNA COVID-19 Vaccine Safety in Pregnant Persons. *New England Journal of Medicine*. 2021 Apr 21.
9. Magnus Maria, Gjessing Hakon, Eide Helena, et al. (2021). Covid-19 Vaccination during Pregnancy and First-Trimester Miscarriage [letter to the editor]. *New England Journal of Medicine*. 2021 Oct 20.
10. Morris, Randy (2021). SARS-CoV-2 spike protein seropositivity from vaccination or infection does not cause sterility. *F & S Reports*. 2021 Sep.
11. Shanes Elisheva, Otero Sebastian, Mithal Leena, et al. (2021). Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccination in Pregnancy Measures of Immunity and Placental Histopathology. *Obstetrics and Gynecology*. 2021 Aug.
12. Male, Victoria (2021). Menstrual Changes After COVID-19 Vaccination. *BMJ*. 2021 Sep 16.
13. New study into COVID-19 vaccine dose interval for pregnant women launches in Southampton. University of Southampton News. Published online August 7, 2021
14. FDA Press Release. FDA Takes Additional Actions on the Use of a Booster Dose for COVID-19 Vaccines. Updated online October 20, 2021.

